

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>COATS LONNEL</u>  (Last) (First) (Middle) <u>C/O BLUEPRINT MEDICINES CORPORATION</u> <u>45 SIDNEY STREET</u>  (Street) <u>CAMBRIDGE MA 02139</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Blueprint Medicines Corp [ BPMC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/20/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/20/2024		M <sup>(1)</sup>		7,500	A	\$69.79	20,754	D	
Common Stock	11/20/2024		M <sup>(1)</sup>		1,312	A	\$76.24	22,066	D	
Common Stock	11/20/2024		S <sup>(1)</sup>		4,500	D	\$93.15 <sup>(2)</sup>	17,566	D	
Common Stock	11/20/2024		S <sup>(1)</sup>		5,287	D	\$94.24 <sup>(3)</sup>	12,279	D	
Common Stock	11/20/2024		S <sup>(1)</sup>		213	D	\$94.99 <sup>(4)</sup>	12,066	D	
Common Stock	11/21/2024		S <sup>(1)</sup>		9,824	D	\$94.87	2,242	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$69.79	11/20/2024		M <sup>(1)</sup>			7,500		(5)	06/21/2028	Common Stock	7,500	\$0	0	D	
Stock Option (Right to Buy)	\$76.24	11/20/2024		M <sup>(1)</sup>			1,312		(6)	06/24/2030	Common Stock	1,312	\$0	3,188	D	

**Explanation of Responses:**

- Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported is an average price. The shares were sold in multiple transactions ranging from \$92.71 to \$93.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).
- The price reported is an average price. The shares were sold in multiple transactions ranging from \$93.74 to \$94.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).
- The price reported is an average price. The shares were sold in multiple transactions ranging from \$94.74 to \$95.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4).
- This option was granted on June 21, 2018 and is fully vested as of the transaction date.
- This option was granted on June 24, 2020 and is fully vested as of the transaction date.

/s/ Melissa Masse, Attorney-in-Fact 11/22/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

